Johnson & Johnson Receives FDA Fast Track Designation for Alzheimer’s Treatments
Thursday, January 09, 2025
Johnson & Johnson has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational monoclonal antibody (mAb), posdinemab, aimed at treating early Alzheimer’s disease (AD).
Alzheimer’s disease is a progressive neurodegenerative condition characterised by memory loss and cognitive decline. It impacts daily life, often requiring round-the-clock care in advanced stages. With no current cure, new therapeutic options are urgently needed.
Posdinemab is an investigational monoclonal antibody that binds to pathological phosphorylated tau. It neutralises the protein before it spreads to other neurons, a process linked to the progression of Alzheimer’s disease. Preclinical studies have indicated its effectiveness in reducing tau seeding in laboratory and animal models.
Developed internally, posdinemab targets phosphorylated tau, a protein linked to Alzheimer’s pathology. Currently under evaluation in the Phase 2b “AuTonomy” study, the antibody has shown promise in non-clinical studies for reducing tau aggregation and preventing the spread of pathological tau in the brain.
This marks the second Fast Track designation granted in 2024 to Johnson & Johnson’s Alzheimer’s portfolio. Earlier this year, the FDA granted the designation to JNJ-2056, the company’s investigational active immunotherapy targeting tau in individuals with preclinical Alzheimer’s disease.
JNJ-2056 is being assessed in the ongoing Phase 2b “ReTain” study for its ability to activate the immune system to combat pathological tau, with the aim of delaying symptom onset and disease progression.
The Fast Track process is designed to accelerate the review of treatments that address serious conditions with high unmet needs, facilitating earlier access for patients.
Globally, Alzheimer’s disease accounts for 60–80% of dementia cases, affecting millions of individuals and posing significant challenges for patients, caregivers, and healthcare systems. Efforts to develop innovative therapies, such as posdinemab and JNJ-2056, aim to address this critical healthcare challenge.
The company continues to advance research to address the unmet needs of individuals affected by Alzheimer’s disease worldwide.
Source: jnj.com
